BOOK NOW & SAVE UP TO $500

May 21-23, 2018 | Boston, MA, USA

www.ckd3-summit.com

CKD3

Chronic Kidney Disease Drug Development



Confidently Demonstrate Greater Therapeutic Efficacy than the Current Standard of Care

21 Expert Speakers Including:

Matthew Breyer
Former Chief Scientific Officer Lead Generation Biotechnology Discovery Research
Eli Lilly & Co

Christina Nowack
Global Clinical Leader
Bayer

Caroline Fox
Vice President, Genetics & Pharmacogenomics
Merck

Maria-Chiara Magnone
Senior Director, Head of Translational Sciences Cardiovascular & Metabolic Diseases
AstraZeneca

"Enjoyed the meeting and all the speakers. Great for meeting colleagues in many areas" **Boehringer Ingelheim**

Tel: +1 617 455 4188 **Email: info@hansonwade.com**

hansonwade

Chronic Kidney Disease Drug Development Summit

Identify the Next Generation of Druggable Targets, Establish Biomarkers for More Confident Patient Stratification, & Understand the Pharmacoeconomics of Next Generation Candidates

CKD3 is the industry's **first end-to-end meeting** which **tackles the challenges drug developers face in developing more efficacious therapeutics targeting CKD.**

Built with AstraZeneca, Eli Lilly and AbbVie this focused summit will share the latest developments, insights and science that are reviving the field by demonstrating greater efficacy than the current standard of care.

Join fellow thought-leaders in the field to:

- Evaluate innovations in clinical trial design needed to overcome challenges in demonstrating efficacy in CKD, including regulatory hurdles regarding proteinuria as a surrogate endpoint
- Deepen your understanding of underlying molecular drivers in CKD for the identification of biomarkers and to inform precision medicine therapeutics
- Outline advancements in stratifying patient populations based upon fast vs slow progressing disease, responder vs non-responders to CKD therapies

You will leave this comprehensive forum equipped with the knowledge and connections to confidently power through the next 12 months of your research and better inform your candidate decisions.

What Previous Hanson Wade Event Attendees Have Said:

"An effective forum to network and learn the most recent progress on several areas"
MedImmune

"Very valuable useful information – one of the best meetings I've ever attended"
Takeda

"This conference was of outstanding value. First class presentations, great opportunity for networking and perfect logistics"
AstraZeneca

Top 5 Reasons to Attend CKD3:

1. **Explore the latest scientific understanding of pathologies** driving CKD progression with Biogen and Sanofi to better inform novel drug discovery targets

2. **Investigate recent findings in biomarker development** with Pfizer and University of Michigan to more quickly determine efficacy of drugs and stratify patients for optimized clinical trials

3. **Overview the potential benefits, safety and adverse effects** of emerging therapeutics with Bayer to analyze and inform next generation therapeutic decisions

4. **Address the limitations of preclinical models** with Amgen and collectively discuss the innovation needed to improve translatability into the clinic

5. **Discuss the reality and clinical perspective** of next generation therapeutics achieving greater efficacy and pharmacoeconomic benefit compared to current standards of care in roundtables

Tel: +1 617 455 4188 Email: info@hansonwade.com
www.ckd3-summit.com

hansonwade

21 Expert Speakers

Ali Hariri
Sanofi

Amrendra Ajay
Instructor of Medicine
Harvard Medical School

Andrew King
Senior Director, Discovery Biology & Translational Science
Ardelyx

Bert Oehlen
Principal Investigator in Renal & Liver Disease
Angion Biomedica

Bruce Riser
Chief Executive Officer
BLR Bio

Caroline Fox
Vice President, Genetics & Pharmacogenomics
Merck

Christina Nowack
Global Clinical Leader
Bayer

Daniel Lin
Principal Scientist, Cardiometabolic Disorders Research
Amgen

George Bakris
Director, Comprehensive Hypertension Centre
University of Chicago

Heather Ascani
Business Operations, Applied Systems Biology Core Internal Medicine – Nephrology
University of Michigan

Jeremy Caldwell
Executive Vice President & Chief Scientific Officer
Ardelyx

Jeremy Duffield
Global Head of Human Biology
Vertex Pharmaceuticals

Joseph Bonventre
Chief Renal Division
Brigham & Women's Hospital

Mahmoud Logham-Adham
Consultant

Maria-Chiara Magnone
Senior Director, Head of Translational Sciences Cardiovascular & Metabolic Diseases
AstraZeneca

Matthew Breyer
Former Chief Scientific Officer, Lead Generation Biotechnology Discovery Research
Eli Lilly & Co

Matthias Kretzler
Professor of Medicine Nephrology/ Internal Medicine, & Computational Medicine & Bioinformatics
University of Michigan

Shuyu Rein
Scientist II
Biogen

Tony Johnson
Chief Executive Officer
Goldfinch Bio

Venkata Sabbisetti
Instructor of Medicine
Harvard Medical School

Vishal Vaidya
Director, Global Biomarker Analytics Lead
Pfizer

"The meeting allowed us time to really engage with the attendees rather than just the few minutes we might have at a tradeshow"
Lonza

Conference Day One | Tuesday, May 22

8.50 Chair's Opening Remarks

Adhering to & Delivering Beyond Regulatory Requirements

Jeremy Duffield
Global Head of Human Biology
Vertex Pharmaceuticals

9.00 Keynote: Mapping the Future for CKD Therapeutics: Why we've Failed & What Needs to be Done for Success

- Assessing multiple clinical trial failures and understanding why in retrospect these failed
- Learning from failings to inform future candidate decisions
- Hypothesizing what is needed for success and what success will look like

9.30 Speed Networking

This session is the ideal opportunity to get face-to-face time with the rest of the CKD community to hear their personal insights and establish meaningful relationships to pursue for the rest of the conference.

10.00 Morning Refreshments & Networking

Identification & Validation of Novel Biomarkers in Chronic Kidney Disease

Maria-Chiara Magnone
Senior Director, Head of Translational Sciences Cardiovascular & Metabolic Diseases
AstraZeneca

11.00 Molecular Reclassification of Underlying Molecular Drivers for Identification of Biomarkers & Precision Medicine Therapeutics

- Classifying disease pathways rather than patient phenotypes to identify molecular fingerprints for respondent populations
- Translating molecular understanding into identifying signature biomarkers for population cohorts
- Mapping molecular triggers for targeting candidates

Vishal Vaidya
Director, Global Biomarker Analytics Lead
Pfizer

11.30 Multi-Omics Approach to Identifying & Validating Biomarkers Representative of Population Cohorts

- Overviewing the biomarker and discovery development pipeline
- Discussing vignettes of translational biomarker science for kidney disease
- Evaluating the potential of biomarkers being therapeutic targets for kidney fibrosis

Bruce Riser
Chief Executive Officer
BLR Bio

12.00 Identification & Validation of a Novel Biomarker in Chronic Kidney Disease

- Examining the gaps in current biomarkers/tests available for CKD
- Reviewing the concept of novel, non-invasive biomarkers able to identify patients at risk, stratifying fast vs slow progressing disease and providing feedback on responder vs non-responders to CKD therapeutics
- Mapping out how a biomarker in development can be used alongside a specific therapeutic but also have universal application for other therapies

12.30 Lunch & Networking

Perspectives Assessing the Potential & Perceived Added Value for Emerging CKD Therapeutics

Amrendra Ajay
Instructor of Medicine
Harvard Medical School

1.30 Molecular & Cellular Therapeutic Targets of Chronic Kidney Disease
- Discussing unpublished data on novel therapeutic targets for CKD
- Highlighting a focus on targeting a specific cell type to influence fibrosis

2.00 Think Tank Roundtable Sessions

More practical and highly interactive breakout roundtables where attendees can crowd-source and share opinions around pre-assigned topic areas. A valuable chance for attendees to unite around hot topics and debate best practice. No more sitting quietly - this is a dedicated opportunity for you to voice your experiences and identify unique solutions.

Topics to be covered include:

1. What will future therapeutics for non-responder populations to SGLT2 Inhibitors and Mineralocorticoid Receptor Antagonists be and what is this opportunity from a business development perspective?

2. Which combinations of surrogate endpoints may hold value in clinical practice as well as in clinical trials?

3. What benefits will payers need to see above and beyond the current standards of care?

4. How to design clinical trials to best show incremental benefits of novel therapeutics?

2.30 Moderator Feedback & Audience Debate

Moderators will be assigned to each roundtable to facilitate discussion and collate the findings. Following the roundtables, they will present back to the entire delegation as part of a panel discussion for information dissemination.

3.00 Afternoon Refreshments & Networking

Better Recapitulating Human CKD in Preclinical Models to Improve Preclinical Drug Development

Daniel Lin
Principal Scientist, Cardiometabolic Disorders Research
Amgen

4.00 Animal Models & Preclinical Drug Discovery for Chronic Kidney Disease
- Discussing lessons learnt from preclinical CKD drug development so far
- Mapping out novel strategies in drug discovery for CKD

Jeremy Duffield
Global Head of Human Biology
Vertex Pharmaceuticals

Daniel Lin
Principal Scientist, Cardiometabolic Disorders Research
Amgen

Jeremy Caldwell
Executive Vice President & Chief Scientific Officer
Ardelyx

4.30 **Panel Discussion: Assessing the Current & Future Landscapes for Preclinical Models**

Shared insight from key opinion leaders with focus on:

- Dissecting the advantages and disadvantages of current, established preclinical models
- Ascertaining what should be done to improve translatability of *in vivo* models without extending drug development timeline
- Asking the question: how achievable are animal models reflective of CKD polygenic in origin?
- Overcoming challenges of translating anti-fibrotic therapeutics into the clinic

5.00 **Chair's Closing Remarks**

5.10 **Scientific Poster Session**

After formal presentations have finished, the learning and networking carries on.
The Poster Session allows you to connect with your peers in a relaxed atmosphere and continue to forge new and existing relationships.
During this session scientific posters will be presented on the latest advancements in next generation therapeutics, innovation in preclinical models and identification of biomarkers to enhance preclinical drug development and patient stratification in clinical trials.

"Conference organizers from Hanson Wade were excellent and very professional"
Ardelyx Inc.

Conference Day Two | Wednesday, May 23

8.20 Chair's Opening Remarks

Discussing the Latest Understanding of Next Generation Therapeutics Mode of Action & Potential

Bert Oehlen
Principal Investigator in Renal & Liver Disease
Angion Biomedica

8.30 Aldosterone Synthase Inhibition: A New Approach to Target an Old Pathway

- Evaluating why despite initial success in reducing aldosterone, concentration will return to pre-treatment levels in large proportions of patients
- Discussing inhibiting aldosterone synthase (AS), the key enzyme responsible for aldosterone production to avoid this 'aldosterone escape'
- Demonstrating potent and selective small molecule inhibitors of AS
- Reviewing this activity in several preclinical animal models of CKD

Bruce Riser
Chief Executive Officer
BLR Bio

9.00 Developing a Next Generation Therapy – Investigating a Novel Pathway for Drug Development

- Examining a novel discovery with unique mode of action and the potential to halt, maybe even reverse, the progression of CKD
- Mapping out key early scientific findings that have been critical for the advancement from concept to active drug
- Reviewing important efficacy data emerging related to different progression pathways impacted by the drug
- Evaluating strategy and resulting safety of the drug, based upon currently available animal data

Partnership Strategies to Optimize Drug Development in CKD

Heather Ascani
Business Operations, Applied Systems Biology Core
Internal Medicine – Nephrology
University of Michigan

9.30 Private Partnership Strategies for Drug Development in CKD

- Strategizing how academia and industry can work jointly for development of novel therapeutics in kidney disease
- Outlining and detailing the success different approaches in place from University of Michigan to implement public private partnership strategies for CKD

10.00 Morning Refreshments & Networking

Progression Towards Precision Medicine in CKD Therapeutics

Caroline Fox
Vice President, Genetics & Pharmacogenomics
Merck

11.00 Using Human Genetics to Drive Development - the Industry Perspective

- Understanding the genetic and environmental causes of chronic kidney disease for novel insights into renal physiology and pathophysiology and insights into identification of novel therapeutic or preventative targets
- Applying genetics and genomics to improve clinical trial efficacy in CKD
- Outlining the landscape for CKD biomarkers discovered using genomics

Matthias Kretzler
Professor of Medicine Nephrology/ Internal Medicine, & Computational Medicine & Bioinformatics
University of Michigan

11.30 Precision Medicine in Kidney Disease: System Biology Driven CKD Target Identification

- Summarizing how precision medicine approach can be implemented for kidney disease
- Focusing on identification of molecule defined subgroups of patients
- Defining molecular outcome predictors and pathways for targeted therapeutic attack in CKD

Tony Johnson
Chief Executive Officer
Goldfinch Bio

12.00 A Novel Approach for Precision Medicine in Kidney Diseases

- Discussing novel targets modulating FSGS and Diabetic Nephropathy pathways, revealed from combining whole genome sequencing and multi-omics
- Overviewing the development of a subsequently identified candidate
- Showcasing an IND filed 4Q18 to treat molecularly-defined FSGS patients using relevant biomarker(s)

Shuyu Rein
Scientist II
Biogen

12.30 PDGFR Signalling Promoting Organ Dysfunction by Activating Innate Immunity & PAI-1 Dependent Matrix Deposition in the Fibroblast

- An overview of PDGF signalling importance on the regulation of innate immunity of fibroblasts
- Discussing PAI-1 as a critical downstream mediator and target of PDGF signalling pathway
- Demonstrating a new mechanism that PDGF modulates for fibrogenetic gene expression in a post-translational manner
- Targeting both PDGF or PAI-1 as efficient ways for treatment of CKD

1.00 Lunch & Networking

Understanding the Cardio-Renal Relationship to Better Inform Further Drug Development Decisions

Christina Nowack
Global Clinical Leader
Bayer

2.00 Evaluating the Potential Benefits, Safety & Adverse Effects of a New Class of Mineralcorticoid Receptor Antagonists (MRA) on the Progression of DKD – FIGARO-DKD & FIDELIO-DKD

- Understanding the rationale for use of MRAs in patients with CKD/DKD
- Discussing historical results and obstacles
- Overviewing the Bayer FIGARO-DKD and FIDELIO-DKD trial including background information about the studies

Andrew King
Senior Director, Discovery Biology & Translational Science
Ardelyx

2.30 Phosphate Control in CKD & ESRD

- Addressing the issues of current approved agents used to treat hyperphosphatemia including phosphate binders
- Demonstrating how novel small molecule agents which reduce serum phosphate in ESRD could be game changing for treatment of hyperphosphatemia
- Outlining how Tenapanor, a clinically validated minimally systemic NHE3 inhibitor, reduces serum phosphate, and has potential to address the unmet need in treatment of hyperphosphatemia

3.00 Afternoon Refreshments & Networking

Harnessing the Understanding of CKD Molecular Pathology for Identification of Druggable Targets

Joseph Bonventre
Chief Renal Division
Brigham & Women's Hospital

4.00 The Continuum of Acute & Chronic Kidney Disease

- Discussing the determining factors in adaptive vs maladaptive repair
- Evaluating the role of DNA damage
- Overviewing how the cell cycle plays a role in maladaptive repair

Matthew Breyer
Former Chief Scientific Officer Lead Generation Biotechnology Discovery Research
Eli Lilly & Co

Ali Hariri
Sanofi

George Bakris
Director, Comprehensive Hypertension Centre
University of Chicago

4.30 Panel Discussion: Objectively Reviewing Common Pathways & Mechanisms Across Different CKD Pathologies & Evaluating Opportunities to Learn from Successful & Failed Therapeutics

- Shared insight from leading experts into the mechanistic triggers and pathways within distinct subsets of chronic kidney diseases including:
  - Diabetic Nephropathy
  - Polycystic Kidney Disease
  - Focal Segmental Glomerulosclerosis (FSGS)
- Rationalizing whether insight into the successful and failed therapeutics for homogenous kidney disease can inform decisions to target heterogeneous kidney diseases
- Reviewing whether fibrosis is a cause or consequence of CKD and rationalizing the potential for common anti-fibrotic therapeutics demonstrating efficacy in the clinic

George Bakris
Director, Comprehensive Hypertension Centre
University of Chicago

5.00 Keynote: Changing the Trajectory of CKD Diabetes: Where are we?

- Evaluating the changes in CKD progression trends over the past 30 years in people with diabetes
- Looking at the impact of blood pressure control and drug classes on CKD progression
- Evaluating the impact of drug classes on reduced CKD progression in diabetes

5.30 Chairs Closing Remarks

Pre-Conference Workshop Day | Monday, 21 May

Workshop A

Innovative Trial Designs to Overcome Challenges in Demonstrating Efficacy in CKD

10:00 - 1:00

CKD clinical trials are costly investments for drug developers in both time and funds; yet high quality clinical trials are fundamental to evidence-based prevention and efficacious treatment. Selecting valid and appropriate endpoints that are achievable is a fundamental progression needed for the CKD field.

Join this workshop to discuss:

- Harnessing lessons learnt from positive case studies in polycystic kidney disease and IgA nephropathy
- Confidently achieving patient selection and stratification to accelerate clinical trials in autosomal dominant polycystic kidney disease, IgA nephropathy and other glomerular diseases
- Evaluating the role of biomarkers and surrogate endpoints in CKD clinical trials
- Regulatory hurdles regarding proteinuria as surrogate endpoint

Workshop Leader
Mahmoud Loghman-Adham
Consultant

Mahmoud Loghman-Adham, MD is a pediatric nephrologist by training, currently a consultant to pharmaceutical and biotech industry. Most recently, he was a Medical Director at Baxalta (now part of Shire). He provides strategic medical and scientific advice on clinical trial design and execution and on business development. Prior to joining Baxalta, he was a Senior Medical Director and a Translational Medicine Leader at Hoffmann-La Roche Inc. He has led clinical trials from Phase 2 to 4 in anemia, renal diseases, inflammatory and autoimmune diseases, emphysema/COPD, and hematology /oncology and worked on biomarker identification and incorporation into proof-of-concept clinical trials.

Workshop B

Exploring Biomarkers in CKD to Confidently Profile Patient Sub-Populations

2:00 - 5:00

Whilst there are undoubtedly leading targets within the chronic kidney disease therapeutic landscape, the heterogeneity of the disease means non-responsive populations are inevitable.

In order to optimize clinical trials for future candidates biomarkers identifying drug responsive cohorts, faster progressing CKD patients and persons likely to show CVD outcomes are essential.

Attend this workshop to profile patient sub-populations, understand how best to target them, and map out what we know about viable, translatable biomarkers for them.

This workshop will comprehensively cover:

- Objectively assessing the current preclinical and clinical biomarker landscape. What do we have? What do we need?
- How to overcome challenges coupling de novo drug development to de novo biomarker development
- Improving the translatability of biomarkers to more robustly translate into the clinic and provide greater context to preclinical findings
- Discussing the potential for biomarkers to stratify populations and optimize clinical trial design

Workshop Leader
Venkata Sabbisetti
Instructor of Medicine
Harvard Medical School

Venkata Sabbisetti is an Instructor of Medicine at Harvard Medical School where he is the Director of the Biomarker Laboratory established by the CKD Biomarker Consortium, and an Associate Biologist at Brigham and Women's Hospital. He specializes in the identification, development and application of biomarker strategies to demonstrate and evaluate efficacy of novel therapeutics in kidney diseases, with a particular focus on evaluating biomarkers for preclinical drug development.

Partnership Opportunities

Why Partner?

Research with Boehringer Ingelheim, Bayer, AstraZeneca and many others, shows that drug developers are **actively seeking partners to optimize clinical trial design to minimize costs and save time**. They are keen to **understand innovations in preclinical models** that address the failings of translating candidates to clinic to date.

Partnering with CKD3 is your opportunity to **demonstrate your experience and credibility to the chronic kidney disease field**. Your brand, your message, your reputation showcased in front of the leading minds of CKD drug development.

We'll work with you to **build a bespoke partnership to guarantee that you meet your 2018 business objectives**. Whether you need to communicate exciting progress to the field's decision makers, are looking to enhance or generate leads or would like to get a grasp of next generation investments in this market, you can rely on our ability to advise on, and deliver the right solution for you.

To learn more about how we can support your efforts, get in touch today at **sponsor@hansonwade.com**

Audience Seniority*



Attending Companies*



*Based on market research and previous events' statistics

Anticipated Companies Attending:

ACCELERON · Allergan · AstraZeneca · BAYER · Bristol-Myers Squibb · CHUGAI · Lilly · Genentech A Member of the Roche Group · Gilead · Intercept · MedImmune A member of the AstraZeneca Group · MERCK · NOVARTIS · Pfizer · Roche

Become a Partner

Jakub Nunuk
Partnership Manager
Tel: +1 617 455 4188
Email: sponsor@hansonwade.com

Ready to Register?

3 Easy Ways To Book

www.ckd3-summit.com/register

Tel: +1 617 455 4188

Email: info@hansonwade.com

1. Harness the latest understanding of molecular pathology to identify the next generation of druggable targets
2. Establish biomarkers for more efficient preclinical drug development and patient stratification
3. Understand the efficacy and pharmacoeconomic benefits of next generation candidates in the clinic

Team Discounts*

- **10% discount – 3 delegates**
- **15% discount – 4 delegates**
- **20% discount – 5 or more delegates**

Please note that discounts are only valid when three or more delegates from one company book and pay at the same time.

Contact: register@hansonwade.com

Secure Your Place

Package Details	Register & Pay before Friday February 9, 2018	Register & Pay before Friday March 16, 2018	Register & Pay before Friday April 13, 2018	Standard Pricing
GOLD Conference + 2 Workshops	$3697 **(save $500)**	$3797 **(save $400)**	$3897 **(save $300)**	$3997 **(save $200)**
SILVER Conference + 1 Workshop	$3098 **(save $400)**	$3198 **(save $300)**	$3298 **(save $200)**	$3398 **(save $100)**
BRONZE Conference Only	$2499 **(save $300)**	$2599 **(save $200)**	$2699 **(save $100)**	$2799
Workshops (each)	$699			

*Special 40% off for academics available upon request

VENUE

Hyatt Regency Boston 1 Ave de Lafayette, Boston, MA, 02111, USA

For further information or assistance, please www.boston.regency.hyatt.com